SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

[1]  R. Govindan,et al.  Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ying Cheng,et al.  Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. , 2022, JAMA.

[3]  P. Hegde,et al.  Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation , 2022, bioRxiv.

[4]  Ying Cheng,et al.  Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2022, The Lancet. Oncology.

[5]  H. Mann,et al.  Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN , 2022, ESMO open.

[6]  L. Paz-Ares,et al.  Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Q. Song,et al.  Brain Metastasis in Patients with Small Cell Lung Cancer , 2021, International journal of general medicine.

[8]  L. Paz-Ares,et al.  PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial , 2021, Journal of Thoracic Oncology.

[9]  K. Nackaerts,et al.  Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  G. Sánchez-Benavides,et al.  Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Bosch-Barrera,et al.  Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry , 2021, PloS one.

[12]  C. Gwaltney,et al.  Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. , 2021, Clinical lung cancer.

[13]  D. de Ruysscher,et al.  Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675). , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  S. Gettinger,et al.  Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Derek E. Smith,et al.  Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. , 2020, JAMA oncology.

[16]  C. Rudin,et al.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Peters,et al.  Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. , 2020, The Lancet. Oncology.

[18]  Young Hak Kim,et al.  Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.

[19]  Ming Chen,et al.  Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses—reply , 2019, Cancer.

[20]  M. Lawrence,et al.  Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. , 2019, Cancer discovery.

[21]  B. Jeremic,et al.  Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. , 2019, European journal of cancer.

[22]  V. Remouchamps,et al.  Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[24]  C. Rudin,et al.  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Sheng,et al.  Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis , 2018, Journal of Cancer.

[26]  A. Ganti,et al.  Surgery for limited-stage small cell lung cancer: ready for prime-time? , 2017, Journal of thoracic disease.

[27]  C. Simone,et al.  Outcomes of Stereotactic Body Radiotherapy for T1‐T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis , 2017, Clinical lung cancer.

[28]  A. Bezjak,et al.  Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial , 2017, The Lancet. Oncology.

[29]  E. Smit,et al.  Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. , 2017, Lung cancer.

[30]  T. Yamanaka,et al.  Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[31]  J. Debus,et al.  Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation. , 2016, Lung cancer.

[32]  H. Choy,et al.  Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[34]  S. Senan,et al.  Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. , 2016, Clinical lung cancer.

[35]  C. Faivre-Finn,et al.  Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial , 2015, The Lancet.

[36]  J. Pignon,et al.  Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  W. Curran,et al.  A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  A. Rossi,et al.  Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Faivre-Finn,et al.  Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. , 2012, Lung cancer.

[40]  D. Kondziolka,et al.  Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.

[41]  E. Felip,et al.  Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  J. Jett,et al.  Prognostic factors differ by tumor stage for small cell lung cancer , 2009, Cancer.

[43]  R. Arriagada,et al.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. , 2009, The Lancet. Oncology.

[44]  S. Ou,et al.  Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  L. Collette,et al.  Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.

[46]  T. Ciuleanu,et al.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Edward L Spitznagel,et al.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Arriagada,et al.  Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer. , 2001, The New England journal of medicine.

[49]  J. Lafitte,et al.  A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. , 2000, Lung cancer.

[50]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[51]  B. Jeremic,et al.  Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  H. Hansen,et al.  Surgery in limited stage small cell lung cancer. , 1999, Cancer treatment reviews.

[53]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[55]  A. Polyzos,et al.  Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide. , 1998, Journal of chemotherapy.

[56]  V. Remouchamps,et al.  Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. , 2017 .

[57]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .